Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Candel Therapeutics Inc. Common Stock
CADL | US
6.50
USD-0.54
-7.67%
CADL | US
Loading StockChartView...
About Candel Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
6.50
Open
7.04
High
7.05
Low
6.39
Candel Therapeutics Inc. a clinical stage biopharmaceutical company engages in the development immunotherapies for the cancer patients. It develops CAN-2409 which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110 which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the"enLIGHTEN Discovery Platform a systematic iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene Inc. and changed its name to Candel Therapeutics Inc. in November 2020. Candel Therapeutics Inc. was incorporated in 2003 and is based in Needham Massachusetts."
View LessCADL | US
Risk
108.2
Sharpe
0.43
Luna's Score
43/100
Recommendation
Sell
Luna says (CADL | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
137.9%1 month
108.2%3 months
82.5%6 months
74.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
27.77
Debt to equity
-1.86
Debt to assets
0.70
Ent. to EBITDA
-0.01
Ent. to rev.
821.98
PEG
-
Other Fundamentals
EBITDA
-34.66M
MarketCap
208.55M
MarketCap(USD)
208.55M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-480.68
Short ratio
5.13
Short perc.
7.19
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.90
Range1M
3.21
Range3M
3.21
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.01
Price X volume
10.99M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.01 | 0.53 | Cheaper |
| Ent. to Revenue | 821.98 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 27.77 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 82.50 | 72.80 | Par |
| Debt to Equity | -1.86 | -1.23 | Cheaper |
| Debt to Assets | 0.70 | 0.25 | Expensive |
| Market Cap | 208.55M | 3.66B | Emerging |
